Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Gains from Investment Securities (2018 - 2025)

Neurogene (NGNE) has disclosed Gains from Investment Securities for 4 consecutive years, with -$8000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Investment Securities changed N/A year-over-year to -$8000.0, compared with a TTM value of -$8000.0 through Sep 2025, up 93.28%, and an annual FY2024 reading of $52000.0, up 79.31% over the prior year.
  • Gains from Investment Securities was -$8000.0 for Q4 2024 at Neurogene, down from $33000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.3 million in Q1 2020 and bottomed at -$200000.0 in Q2 2020.